Literature DB >> 12404053

Clinical outcome of simultaneous self-expandable metal stents for palliation of malignant biliary and duodenal obstruction.

M Kaw1, S Singh, H Gagneja.   

Abstract

BACKGROUND: Previous studies have shown that self-expanding metal stents are an effective method for palliation of malignant biliary or duodenal obstruction. We present our experience with the use of simultaneous self-expandable metal stents for palliation of malignant biliary and duodenal obstruction.
METHODS: We performed a retrospective review of all patients undergoing simultaneous biliary and duodenal self-expandable metal stent placement between November 98 and May 2001. All the patients had documented evidence of biliary obstruction and symptomatic duodenal obstruction. The patients received endoscopic biliary stenting with biliary Ultraflex or Wallstents, and endoscopic duodenal stenting using enteral Wallstents. They were followed until their death.
RESULTS: We identified 18 patients (11 men and 7 women) whose mean age was 65 years, (range, 46-85 years). Malignancies included pancreatic 14 (78%), biliary 2 (11%), lymphoma 1 (5%), and metastatic 1 (5%) disorders. Ten patients previously had plastic biliary stents placed for past malignant biliary obstruction (4 patients had recurrent biliary obstruction). All the patients had evidence of duodenal obstruction. Combined metal stenting was successful in 17 patients. One procedure failed due to a tortuous duodenal stricture. All the patients had effective palliation of biliary obstruction, as evidenced by a decrease in the level of total bilirubin and alkaline phosphatase. Of the 17 patients with successful duodenal stenting, 16 had a good clinical outcome, with relief of obstructive symptoms. No immediate stent-related complications were noted. During the follow-up period, 12 patients died of progression of the underlying malignancy. None of the deaths were stent related. Median survival time was 78 days. Two patients had recurrent biliary obstruction from tumor ingrowth at 45 and 68 days, respectively. Both underwent restenting: one by endoscopic retrograde cholangiopancreatography (ERCP) and the other by percutaneous transhepatic cholangiography (PTC). Two other patients had recurrent duodenal obstruction, respectively, 36 and 45 days after the initial stenting. One obstruction was secondary to tumor ingrowth, and the other was caused by distal stent migration. Both patients had successful duodenal restenting.
CONCLUSION: Combined self-expandable metal stenting for simultaneous palliation of malignant biliary and duodenal obstruction may provide a safe and less invasive alternative to surgical palliation with an acceptable clinical outcome. Simultaneous self-expandable metal stents should be considered as a treatment option for patients who are poor candidates for surgery.

Entities:  

Mesh:

Year:  2002        PMID: 12404053     DOI: 10.1007/s00464-002-8541-3

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  34 in total

1.  Treating bilio-duodenal obstruction: combining new endoscopic technique with 6 Fr stent introducer.

Authors:  Iruru Maetani; Tomoko Nambu; Shigefumi Omuta; Takeo Ukita; Hiroaki Shigoka
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

2.  Duodenal stenting for malignant gastric outlet obstruction: prospective study.

Authors:  Eduardo Guimarães Hourneaux Moura; Flávio Coelho Ferreira; Spencer Cheng; Diogo Turiani Hourneaux Moura; Paulo Sakai; Bruno Zilberstain
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

3.  Management of simultaneous biliary and duodenal obstruction: the endoscopic perspective.

Authors:  Todd H Baron
Journal:  Gut Liver       Date:  2010-09-10       Impact factor: 4.519

4.  Gastroduodenal stenting: is still useful in the treatment of malignant obstruction?

Authors:  Paola Crivelli; Marcello Carboni; Rino Aldo Montella; Antonio Matteo Amadu; Stefano Profili; Maurizio Conti; Giovanni Battista Meloni
Journal:  Radiol Med       Date:  2017-04-20       Impact factor: 3.469

5.  Endoscopic bilio-duodenal bypass: outcomes of primary and revision efficacy of combined metallic stents in malignant duodenal and biliary obstructions.

Authors:  Jorge Canena; João Coimbra; Diana Carvalho; Catarina Rodrigues; Mário Silva; Mariana Costa; David Horta; António Mateus Dias; Isabel Seves; Gonçalo Ramos; Leonel Ricardo; António Pereira Coutinho; Carlos Romão; Pedro Mota Veiga
Journal:  Dig Dis Sci       Date:  2014-05-13       Impact factor: 3.199

6.  Self-expanding metal stents for pancreatic tumors: expanding the possibilities, decreasing the costs and risks.

Authors:  Amy Tyberg; Michel Kahaleh
Journal:  Dig Dis Sci       Date:  2014-11       Impact factor: 3.199

7.  Temporary placement of a covered duodenal stent can avoid riskier anterograde biliary drainage when ERCP for obstructive jaundice fails due to duodenal invasion.

Authors:  Felix Goutorbe; Olivier Rouquette; Aurélien Mulliez; Julien Scanzi; Marion Goutte; Michel Dapoigny; Armand Abergel; Laurent Poincloux
Journal:  Surg Endosc       Date:  2016-06-20       Impact factor: 4.584

8.  Palliative surgical bypass for pancreatic and peri-ampullary cancers.

Authors:  Samrat Mukherjee; Hemant M Kocher; Robert R Hutchins; Satyajit Bhattacharya; Ajit T Abraham
Journal:  J Gastrointest Cancer       Date:  2007

9.  Duodenal metal stent placement is a risk factor for biliary metal stent dysfunction: an analysis using a time-dependent covariate.

Authors:  Tsuyoshi Hamada; Yousuke Nakai; Hiroyuki Isayama; Takashi Sasaki; Hirofumi Kogure; Kazumichi Kawakubo; Naoki Sasahira; Natsuyo Yamamoto; Osamu Togawa; Suguru Mizuno; Yukiko Ito; Kenji Hirano; Nobuo Toda; Minoru Tada; Kazuhiko Koike
Journal:  Surg Endosc       Date:  2012-10-17       Impact factor: 4.584

Review 10.  Treatment of malignant gastric outlet obstruction with stents: an evaluation of the reported variables for clinical outcome.

Authors:  Lene Larssen; Asle W Medhus; Truls Hauge
Journal:  BMC Gastroenterol       Date:  2009-06-17       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.